Genetic-epigenetic interaction modulates μ-opioid receptor regulation

Area of Science:

• Neurogenetics
• Epigenetics
• Pharmacogenomics

Background:

• Genetic variations and epigenetic modifications influence protein expression levels.
• The μ-opioid receptor (MOR) plays a crucial role in pain perception and reward pathways.
• Genetic polymorphisms in the OPRM1 gene are associated with altered receptor function and expression.

Purpose of the Study:

• To investigate the functional consequences of the OPRM1 118A>G (rs1799971) single nucleotide polymorphism (SNP) on MOR expression.
• To elucidate the role of genetic-epigenetic interactions in regulating MOR levels in chronic opiate users.

Main Methods:

• Analysis of OPRM1 DNA methylation status in postmortem brain tissue from Caucasian chronic opiate addicts and controls.
• Genotyping for the OPRM1 118A>G SNP.
• Assessment of MOR expression and mRNA transcription levels.

Main Results:

• The OPRM1 118A>G SNP introduces a novel CpG methylation site at OPRM1 position +117.
• This genetic variant leads to enhanced OPRM1 DNA methylation, impeding MOR upregulation in response to chronic opiate exposure.
• Carriers of the 118G variant showed diminished OPRM1 mRNA transcription and absent receptor upregulation, unlike wild-type subjects.

Conclusions:

• The OPRM1 118A>G SNP mediates its functional effects through a genetic-epigenetic interaction, reducing MOR expression.
• This mechanism impairs the opioid system's compensatory response to chronic opiate exposure.
• Genotype-induced epigenotype changes have significant functional consequences on the opioid system.